DRESDEN, Germany--(BUSINESS WIRE)--Cenix BioScience GmbH (Dresden), the leading specialist in advanced RNA interference (RNAi)-based research services, and Merck KGaA (Darmstadt, Germany), a leading global pharmaceutical company, today announced that they have signed a framework research agreement securing Cenix services to enhance and accelerate Merck target discovery and validation efforts in oncology, with an option to expand in several human disease programs.
